A comparison of the availability of tobramycin for inhalation from vented vs unvented nebulizers

Chest
Allan L CoatesE B Vadas

Abstract

To compare drug output from a vented nebulizer (Pari LC Jet Plus) with a traditional unvented nebulizer (Hudson 1730 T Up-Draft 11) using aerosolized tobramycin, which is frequently used in the treatment of cystic fibrosis. Six nebulizers of each type were filled with a 4 mL tobramycin (80 mg) solution and were driven by a compressor (Pulmo-Aide). Various inspiratory flows (VI) (0, 5, 10, 15, 20 L/min for the Pari LC Jet Plus and 0, 5, and 10 L/min for the Hudson 1730, all at 40% relative humidity) were directed through each nebulizer. Drug output was measured from changes in weight and concentration (assessed by changes in osmometry) within the nebulizer. Particle size distributions were determined by laser diffraction allowing the calculation of the amount of aerosol output in the respirable range (<5 microm). The nebulizers were first run until end-nebulization to establish total drug output and then for either 4 or 5 min to determine the rate of drug output (mg/min) before intermittent aerosol output. The total drug output without VI for both the unvented and the vented nebulizers was not significantly different, 55 (51, 60) mg for the Hudson 1730 vs 51 (49, 53) mg for the Pari LC Jet Plus (mean [95% confidence limits]). In...Continue Reading

References

Dec 1, 1991·Clinical Science·S H ThomasT O Nunan
Dec 1, 1987·The American Review of Respiratory Disease·J S IlowiteG C Smaldone
Sep 1, 1985·Thorax·S P NewmanS W Clarke
Apr 1, 1974·The Journal of Pediatrics·P O AldersonR L Hill
Sep 10, 1983·Lancet·M M ClayS W Clarke
Jun 1, 1994·Pediatric Pulmonology·B W Ramsey, H L Dorkin
Jun 17, 1993·The New England Journal of Medicine·B W RamseyM A McBurnie
Jun 1, 1996·American Journal of Respiratory and Critical Care Medicine·R W WilmottH J Fuchs

❮ Previous
Next ❯

Citations

May 2, 2000·Pediatric Pulmonology·M Ramagopal, L C Lands
Oct 3, 2002·Pediatric Pulmonology·Anne-Marie CanakisAllan L Coates
Dec 4, 2003·International Journal of Pharmaceutics·A H de BoerH W Frijlink
Apr 25, 2003·International Journal of Pharmaceutics·H DiederikD M Barends
Sep 30, 2000·Journal of Aerosol Medicine : the Official Journal of the International Society for Aerosols in Medicine·K NikanderG C Smaldone
Nov 6, 2001·Journal of Aerosol Medicine : the Official Journal of the International Society for Aerosols in Medicine·K NikanderP Wollmer
Aug 10, 2001·Journal of Aerosol Medicine : the Official Journal of the International Society for Aerosols in Medicine·T A StandaertB Ramsey
Jan 17, 2002·Journal of Aerosol Medicine : the Official Journal of the International Society for Aerosols in Medicine·S L HoA L Coates
Nov 7, 2000·Journal of Aerosol Medicine : the Official Journal of the International Society for Aerosols in Medicine·A L CoatesL C Lands
Oct 21, 2010·Journal of Aerosol Medicine and Pulmonary Drug Delivery·Laurent PitanceGiuseppe Liistro
Mar 21, 2013·Journal of Aerosol Medicine and Pulmonary Drug Delivery·Wallace B WeeAllan L Coates
Jan 5, 2013·Journal of Aerosol Medicine and Pulmonary Drug Delivery·L PitanceL Vecellio
Jun 27, 2002·Paediatric Drugs·Isabelle Sermet-GaudelusGérard Lenoir
Dec 22, 2007·Expert Review of Medical Devices·Rajiv Dhand, Harjyot Sohal
Feb 12, 2005·Chest·Ghassan A AlothmanAllan L Coates
Nov 27, 2009·International Journal of Antimicrobial Agents·Matthew E FalagasEugenios I Metaxas
Jan 20, 2009·International Journal of Pharmaceutics·Laurent VecellioPatrice Diot
Aug 3, 2006·The Veterinary Clinics of North America. Equine Practice·Valerie A Brown, Pamela A Wilkins
Jun 30, 2009·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Harry HeijermanUNKNOWN consensus working group
Mar 6, 2010·Postgraduate Medicine·Leonard FromerJohn Walsh
Jan 15, 1999·Pediatric Pulmonology·A L Coates, S L Ho
Dec 8, 2020·Frontiers in Bioengineering and Biotechnology·Caroline MajoralLaurent Vecellio

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.